Drugs / GMC-252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02686281 | Sep 2012 → Jul 2013 | — | Genmedica Therapeutics S.L. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02744820 Comparator | Apr 2016 → Sep 2017 | type 2 diabetes mellitus | Genmedica Therapeutics S.L. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMC-252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02744820 ↗ |
| Route | Oral | “Single ascending oral administrations of GMC-252-L-Lysine Salt” NCT02686281 ↗ |